反应详情

To a solution of (S)-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(iodomethyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.200 g, 0.342 mmol) and (S)-(4-chloro-2-(pent-4-en-2-yloxy)phenyl)methanol (0.093 g, 0.411 mmol) in DMF (1 mL) was added sodium hydride (0.021 g, 0.513 mmol) and the mixture was stirred at rt. After 2 h, the mixture was diluted with EtOAc and washed with water and brine. The organic phase was concentrated and purified by prep-HPLC to afford (S)-2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(((4-chloro-2-((S)-pent-4-en-2-yloxy)benzyl)oxy)methyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetic acid (41.4 mg, 0.063 mmol, 18.47% yield) as an amber glass. LCMS (M+H) calcd for C35H48ClN4O6: 655.32. found: 655.5.

1. washwashed with water and brine
2. concentrationThe organic phase was concentrated
3. custompurified by prep-HPLC